TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. The company was incorporated in 2005 and is headquartered in Fuchu, Japan.
Metrics to compare | 4891 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4891PeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.7x | −8.8x | −0.6x | |
PEG Ratio | −0.20 | −0.13 | 0.00 | |
Price/Book | 1.9x | 3.4x | 2.6x | |
Price / LTM Sales | - | 31.9x | 3.2x | |
Upside (Analyst Target) | 384.4% | 113.8% | 42.3% | |
Fair Value Upside | Unlock | 9.5% | 5.7% | Unlock |